Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline C Sigman

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 2, 2005
New science-based endpoints to accelerate oncology drug developmentGary J Kelloff, Caroline C Sigman
Nature Reviews. Drug Discovery|February 11, 2012
Cancer biomarkers: selecting the right drug for the right patientGary J Kelloff, Caroline C Sigman
Nature Reviews. Cancer|June 15, 2007
Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug developmentGary J Kelloff, Caroline C Sigman
Cancer Prevention Research (Philadelphia, Pa.)|April 30, 2009
Early detection of oral neoplasia: watching with new eyesGary J Kelloff, Caroline C Sigman, Christopher H Contag
Urologic Oncology|March 10, 2015
Biomarker development in the context of urologic cancersGary J Kelloff, Caroline C Sigman, Howard I Scher
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2006
Imaging and oncologic drug developmentWafik S El-Deiry, Caroline C Sigman, Gary J Kelloff
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 14, 2007
The mammalian target of rapamycin pathway as a potential target for cancer chemopreventionLevy Kopelovich, Judith R Fay, Caroline C Sigman, et al.
Molecular Cancer Therapeutics|August 27, 2003
Is inducible nitric oxide synthase a target for chemoprevention?James A Crowell, Vernon E Steele, Caroline C Sigman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 19, 2003
Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancersGary J Kelloff, Joyce A O'Shaughnessy, Gary B Gordon, et al.
Journal of the National Cancer Institute|October 27, 2009
A perspective on challenges and issues in biomarker development and drug and biomarker codevelopmentSheila E Taube, Gary M Clark, Janet E Dancey, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|March 2, 2005
New science-based endpoints to accelerate oncology drug developmentGary J Kelloff, Caroline C Sigman
Nature Reviews. Drug Discovery|February 11, 2012
Cancer biomarkers: selecting the right drug for the right patientGary J Kelloff, Caroline C Sigman
Nature Reviews. Cancer|June 15, 2007
Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug developmentGary J Kelloff, Caroline C Sigman
Cancer Prevention Research (Philadelphia, Pa.)|April 30, 2009
Early detection of oral neoplasia: watching with new eyesGary J Kelloff, Caroline C Sigman, Christopher H Contag
Urologic Oncology|March 10, 2015
Biomarker development in the context of urologic cancersGary J Kelloff, Caroline C Sigman, Howard I Scher
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2006
Imaging and oncologic drug developmentWafik S El-Deiry, Caroline C Sigman, Gary J Kelloff
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 14, 2007
The mammalian target of rapamycin pathway as a potential target for cancer chemopreventionLevy Kopelovich, Judith R Fay, Caroline C Sigman, et al.
Molecular Cancer Therapeutics|August 27, 2003
Is inducible nitric oxide synthase a target for chemoprevention?James A Crowell, Vernon E Steele, Caroline C Sigman, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 19, 2003
Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancersGary J Kelloff, Joyce A O'Shaughnessy, Gary B Gordon, et al.
Journal of the National Cancer Institute|October 27, 2009
A perspective on challenges and issues in biomarker development and drug and biomarker codevelopmentSheila E Taube, Gary M Clark, Janet E Dancey, et al.
Pageof 4